Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems [Yahoo! Finance]
Metagenomi, Inc. (MGX)
Company Research
Source: Yahoo! Finance
EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), which were previously subject to exclusive rights granted to Moderna, Inc. Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1 program, as well as all other rights granted under the collaboration, will be returned as part of the termination. “We are pleased to regain full control of the development of base editing technology and RIGS systems so that we may advance them in areas of significant need, such as Alpha-1 antitr
Show less
Read more
Impact Snapshot
Event Time:
MGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGX alerts
High impacting Metagenomi, Inc. news events
Weekly update
A roundup of the hottest topics
MGX
News
- Metagenomi, Inc. (NASDAQ: MGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial ResultsGlobeNewswire
- Metagenomi, Inc. (NASDAQ: MGX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Metagenomi, Inc. (NASDAQ: MGX) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $6.00 price target on the stock, down previously from $16.00.MarketBeat
MGX
Sec Filings
- 5/14/24 - Form 8-K
- 5/14/24 - Form 10-Q
- 5/10/24 - Form SC
- MGX's page on the SEC website